Section Arrow
Quote
ITRM.NASDAQ
- Iterum Therapeutics plc
(Financial Status)
Quotes are at least 15-min delayed:2024/10/31 20:18 EDT
Last
 1.275
+0.065 (+5.37%)
Day High 
1.3291 
Prev. Close
1.21 
1-M High
2.32 
Volume 
1.53M 
Bid
1.28
Ask
1.3
Day Low
1.24 
Open
1.3 
1-M Low
0.808 
Market Cap 
27.47M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.27 
20-SMA 1.12 
50-SMA 1.12 
52-W High 2.5 
52-W Low 0.705001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/-0.56
Enterprise Value
46.43M
Balance Sheet
Book Value Per Share
-0.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed：2024/10/31 20:18 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.